Related Attributes
Product details
Irbesartan, as a long-acting antihypertensive drug, is the first line of hypertension, and in addition to the treatment of hypertension, for Parkinson's, diabetic nephropathy, and other diseases have demonstrated notable efficacy
There are no significant interactions between Irbesartan and hydrochlorothiazide, digoxin, warfarin, or nifedipine.
When used in combination with diuretics, care should be taken to ensure that blood volume is insufficient or that hypotension can be caused by low sodium. When combined with potassium-preserving diuretics (e.g. aminoglutethimide, etc.), elevated blood potassium should be avoided.
Combination with digitalis analogues such as digoxin, beta-blockers such as atenolol, calcium antagonists such as nitrophenylpyridine, etc. does not affect the pharmacokinetics of each other.
Uses and functions of Irbesartan.
Irbesartan is an angiotensin-1 receptor antagonist antihypertensive drug for the treatment of essential hypertension and type 2 diabetic nephropathy with hypertension.
Irbesartan can inhibit angiotensin II and AT1 receptor binding, inhibit vasoconstriction, reduce vascular resistance, reduce aldosterone secretion, plasma angiotensin II level, and thus play a antihypertensive role.
Pharmacological Effects of Irbesartan Raw.
Irbesartan is an angiotensin II (Angiotensin II, Ang II) receptor inhibitor, which can inhibit the conversion of Ang Ⅰ to Ang Ⅱ, and can specifically antagonise angiotensin-converting enzyme 1 receptor (AT1), and the antagonism of AT1 is greater than that of AT 28,500-fold. By selectively blocking the binding of Ang Ⅱ to AT1 receptor, it can inhibit vasoconstriction and By selectively blocking the binding of Ang II to AT1 receptor, it inhibits vasoconstriction and aldosterone release, producing antihypertensive effect.
Irbesartan does not inhibit angiotensin-converting enzyme (ACE), renin, or other hormone receptors, nor does it inhibit ion channels related to blood pressure regulation and sodium balance.
Production method of Bulk Irbesartan Powder.
Method 1: 1-(Fluorenylmethoxycarbonylamino)cyclopentanecarboxylic acid (I) was amidated to 4-(2-phenylcyano)benzylamine, and the product (Ⅲ) was then hydrolysed to remove the protecting group on N to give compound (Ⅳ).
(Ⅳ) and triethyl orthobutyrate condensed cyclisation to obtain compound (V), and then reacted with sodium azide to form tetrazole to obtain irbesartan.
Method 2: Condensation of 1-(fluorenylmethoxycarbonylamino)cyclopentanecarboxylic acid (I) and compound (Ⅳ), the product was obtained by removing the protecting group on N to obtain compound (Ⅷ), and then reacted with triethyl orthovalerate to obtain the product.
Why choose us?
HRK Factory
About Shipping
Pharmaceutical Intermediate manufacturers
©2022 Xi'an Henrikang Biotech Co., Ltd.,